SCHEMBL5403784

SCHEMBL5403784

CC(C)(C)OC(=O)N(Cc1ccccc1)C(CC=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
HSD17B10 Q99714 1/20 0.41
AKT1 P31749 3/20 0.41
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
NCOR2 Q9Y618 1/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
BACE1 P56817 4/20 0.39
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
CTSS P25774 1/20 0.37
HTT P42858 1/20 0.37
ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4376556 0.83 CHRNB2 (0.40) L3MBTL1MEN1KMT2ACTSSATM
SCHEMBL4384037 0.83 CHRNB2 (0.40) L3MBTL1MEN1KMT2ACTSSATM
SCHEMBL5080915 0.82 MEN1 (0.45) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL5080919 0.82 MEN1 (0.45) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL31667777 0.81 L3MBTL1 (0.50) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL4526992 0.81 L3MBTL1 (0.50) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL25852154 0.78 KMT2A (0.59) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL1799801 0.77 HDAC3 (0.40) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL7320870 0.77 MEN1 (0.50) L3MBTL1ALDH1A1LMNAPOLBHSD17B10
SCHEMBL2736195 0.77 ATM (0.43) L3MBTL1ALDH1A1LMNAPOLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7192983-B2 Improving storage stability by reacting with hydrogen sulfate lithium- containing compound; aspartyl protease inhibitors G.D. SEARLE & CO. (US) 2007-03-20 US disclosed
US-20060074247-A1 N-protected/N-substituted-beta-amino hydroxy sulfonates G.D. SEARLE & CO. (US) 2006-04-06 US disclosed
US-6586627-B1 Blocking carbocyclic oxo, amines such as 2-(bis(phenylmethyl) amino)-3-phenylpropanal to form 2-(Bis(phenylmethyl)amino)-1-hydroxy-3-phenylpropylsulfonic Acid Salts, having storage stability; chemical intermediates for enzyme inhibitors G. D. SEARLE & CO. 2003-07-01 US disclosed
US-6147253-A STABILIZED FORM OF N-PROTECTED/N-SUBSTITUTED ALPHA-AMINO ALDEHYDES G. D. SEARLE & CO. (US) 2000-11-14 US disclosed
EP-0861233-B1 N-PROTECTED/N-SUBSTITUTED-BETA-AMINO HYDROXY SULFONATES SEARLE & CO (US) 2000-05-03 EP disclosed
US-5847201-A N-protected/N-substituted-beta-amino hydroxy sulfonates G.D. SEARLE & CO. (US) 1998-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074247-A1 N-protected/N-substituted-beta-amino hydroxy sulfonates AANAT, AASDHPPT, ALDH7A1 L3MBTL1 3521/4885ALDH1A1 30/4885LMNA 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.